KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Return on Capital Employed (2016 - 2025)

Nektar Therapeutics has reported Return on Capital Employed over the past 15 years, most recently at 0.59% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.59% for Q4 2025, down 16.0% from a year ago — trailing twelve months through Dec 2025 was 0.59% (down 16.0% YoY), and the annual figure for FY2025 was 0.59%, down 22.0%.
  • Return on Capital Employed for Q4 2025 was 0.59% at Nektar Therapeutics, down from 0.52% in the prior quarter.
  • Over the last five years, Return on Capital Employed for NKTR hit a ceiling of 0.29% in Q1 2021 and a floor of 0.71% in Q4 2023.
  • Median Return on Capital Employed over the past 5 years was 0.55% (2022), compared with a mean of 0.53%.
  • Biggest five-year swings in Return on Capital Employed: fell -25bps in 2022 and later rose 28bps in 2024.
  • Nektar Therapeutics' Return on Capital Employed stood at 0.4% in 2021, then crashed by -38bps to 0.56% in 2022, then decreased by -29bps to 0.71% in 2023, then surged by 40bps to 0.43% in 2024, then plummeted by -37bps to 0.59% in 2025.
  • The last three reported values for Return on Capital Employed were 0.59% (Q4 2025), 0.52% (Q3 2025), and 0.63% (Q2 2025) per Business Quant data.